SynthesisJournal of neurology2026
The neurological adverse events of immune check point inhibitors in the treatment of cancer.
Synthesis in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitors (ICIs) have revolutionized cancer treatment with significant improvements in survival rates. With the increase in ICI use in the clinical setting, several case reports and series have described neurological adverse events associated with it. We conducted this systematic review and meta-analysis to estimate the incidence of neurological adverse events among ICI clinical trials.
methodsWe searched PubMed, Embase, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL) on November 25, 2025, using ICI and clinical trial as keywords along with their related MeSH terms. The inclusion criteria involved clinical trials investigating the efficacy or safety of any ICI as the only systemic therapy among never treated patients with cancer. To eliminate the impact of other systemic therapies, trials that used ICIs as an adjuvant to another systemic treatment or included patients previously treated with any systemic therapies were excluded. The incidence and its 95% confidence interval (95%CI) were used as the effect measures in the analysis. Subgroup analyses were conducted based on the type of cancer and number of ICIs used in the trial.
resultsWe included a total of 8,826 patients with cancer from 31 clinical trials. The pooled incidence of neurological adverse events was 1.78 × 10
conclusionTaken all together, the incidence of ICI-related neurological adverse events among patients with cancer is low and estimated at 1 in 5000 patients. Individual data analysis of ICI clinical trials is needed to examine the factors associated with ICI-related neurological adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.